Filing Flows › Keros Therapeutics (KROS) › Recalls, complaints & regulation

Keros Therapeutics (KROS): clinical trials

Keros Therapeutics (KROS) beyond its filings: 1 active clinical trial.

Keros Therapeutics' latest quarter

Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Keros Therapeutics have?

1 active study on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.